期刊文献+

噬血细胞综合征患者血清促红细胞生成素表达水平的研究 被引量:3

Expressions of serum erythropoietin in hemophagocytic syndrome patients
原文传递
导出
摘要 目的:探讨血清促红细胞生成素(EPO)在噬血细胞综合征(HPS)患者中的表达水平及临床意义。方法:收集22例HPS患者及15例健康人血清,分别采用酶联免疫吸附(ELISA)方法检测其血清EPO水平,并与各实验室检查指标进行相关性分析。结果:HPS患者组血清EPO水平显著高于健康对照组,差异有统计学意义(P<0.01),感染相关性HPS患者和肿瘤相关性HPS患者血清EPO水平差异无统计学意义(P>0.05)。检测HPS患者血清EPO水平与采血当日红细胞、血红蛋白、血肌酐、尿素氮、三酰甘油、纤维蛋白原、铁蛋白、NK细胞活性、sCD25水平的相关性,发现其与铁蛋白水平呈正相关关系,与其他各项实验室指标均无相关性。结论:HPS患者血清EPO升高可能与贫血、肿瘤有关,但由于炎性因子抑制了EPO对贫血反应的敏感性,所以与血红蛋白之间并无相关关系。EPO在疾病的发生、发展中可能起到一定作用。 Objective:To investigate the expressions of serum erythropoietin(EPO) in hemophagocytic syndrome(HPS) patients and to evaluate its clinical significance.Method:Serum concentration of EPO in HPS patients and 15 healthy controls were measured by enzyme-linked immunosorbent assay(ELISA).Then the correlation between EPO and laboratory indicators was analyzed.Result:The levels of serum EPO in 22 cases of HPS were significantly higher than in control group(P0.01)and the difference was not statistically significant between infection-associated HPS and tumor-associated HPS(P0.05).EPO level in HPS patients showed positive correlation with serum ferritin after EPO levels and red blood cell counts,hemoglobin counts,serum creatinine,urea nitrogen,triglyceride,fibrinogen,ferritin,NK cell activity and sCD25 levels were detected at the same day.Conclusion:High level of EPO in HPS patients may be associated with anemia and tumor,and there was no correlation between EPO and hemoglobin because of inhibition effect of inflammatory factors.These data indicated that serum EPO may play certain roles in the pathogenesis and the progress of HPS.
出处 《临床血液学杂志》 CAS 2011年第6期659-661,共3页 Journal of Clinical Hematology
基金 首都医学发展科研基金(No:2009-1032) 北京市科技计划首都临床特色应用研究(No:D101100050010005) 北京市留学人员科技活动择优资助项目
关键词 噬血细胞综合征 促红细胞生成素 酶联免疫吸附试验 hemophagocytic syndrome erythropoietin enzyme-linked immunosorbent assay
  • 相关文献

参考文献8

  • 1HENTERJ I, HORNE A C, EGELER R M, et al. HI, H-2004.. Diagnostic and therapeutic guidelines for Hemophagocytic lymphohistiocytosis[J]. Pediatr Blood Cancer, 2007,48 .. 124-- 131.
  • 2JANKA G. Familial and acquired hemophagocytic lymphohistiocytosis[J]. Eur J Pediatr, 2007,166 : 95 -- 109.
  • 3JELKMANN W. Molecular biology of erythropoietin[J].Intern Med,2004,43:649--659.
  • 4JANKA G. Hemophagocytic syndromes [J].Blood Rev, 2007,21,245-- 253.
  • 5INOUE Y, TSUSHIMA H, ANDO K, et al. Chemokine expression in human erythroid leukemia cell line AS-E2: macrophage inflammatory protein- 3alpha/CCL20 is induced by inflammatory cytokines [J].Exp Hematol, 2006,34 : 19 -- 26.
  • 6MORCEAU F, SCHNEKENBURGER M, BLASIUS R, et al. Tumor necrosis factor alpha inhibits aclacino mycin A induced erythroid differentiation of K562 cells via GATA-1 [J]. Cancer Lett, 2006,240 : 203 -- 212.
  • 7COSTA E, LIMA M, ALVES J M, et al. Inflammation, T cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recom- binant human erythropoietin therapy[J]. J Clin Immunol, 2008,28 : 268 - 275.
  • 8王旖旎,王昭,吴林,岑溪南,李渤涛,宁丰,段学章,李娟.多中心72例噬血细胞综合征诊疗分析[J].中华血液学杂志,2009,30(12):793-798. 被引量:98

二级参考文献9

共引文献97

同被引文献27

  • 1康睿,曹励之,俞燕,杨明华,张朝霞,郭碧贇,谢岷,陈英,谭志红,王卓,胡婷,吴秀山.中国儿童急性淋巴细胞性白血病染色体6q16.3~21区域候选肿瘤抑制基因的定位与鉴定[J].生物化学与生物物理进展,2006,33(1):65-71. 被引量:5
  • 2Janka G, zur Stadt U. Familial and acquired hemophagocytic lympho-histocytosis[ J]. Hematology Am Soc Hematol Educ Program,2005 :82-88.
  • 3Zur Stadt U, Beutel K, Kolberg S,et al. Mutation spectrum in childrenwith primary hemophagocytic lymphohistiocytosis ; molecular and func-tional analyses of PRF1, UNC13D, STX11,and RAB27A[ J]. HumMutat,2006,27(1) :62 -68.
  • 4Imashuku S. Clinical features and treatment strategies of Epstein - Burrvims - associated hemophagocytic lymphohistiocytosis [ J]. Crit Rev On-col Hematol, 2002,44(3) :259 -272.
  • 5Dandoy C, Grimley M. Secondary Hemophagocytic Lymphohistiocytosis(HLH) From a Brown Recluse Spider Bite [ J]. Biol Blood MarrowTransplant, 2013 ,19: S246.
  • 6Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis[J]. Eur J Pediatr, 2007,166(2) :95 -109.
  • 7Bode SF, Lehmberg K,Maul - Pavicic A, et al. Recent advances inthe diagnosis and treatment of hemophagocytic lymphohistiocytosis[ J].Arthritis Res Ther, 2012,14(3) :213.
  • 8Gupta S, Weitzman S. Primary and secondary hemophagucytic lympho-histioeytosis : Clinical features,pathogenesis and therapy [ J]. ExpertRev Clinlmmunol,2010,6(1) : 137 -154.
  • 9Henter JI, Home A,Aric6 M, et al. HLH - 2004 : Diagnostic and ther-apeutic guidelines for hemophagocytic lymphohistiocytosis[ J]. PediatrBlood Cancer, 2007,48(2) : 124 - 131.
  • 10Chiossone L, Audonnet S,Chetaille B, et al. Protection from inflamma-tory organ damage in a murine model of hemophagocytic lymphohistiocy-tosis using treatment with IL - 18 binding protein[ J]. Front Immunol,2012,3:239.

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部